Besides indirect cardioprotective effects, SGLT2 inhibitors may also have possible direct myocardial effects not only via the inhibition of Na+/H+ exchanger (NHE) activity but also via the suppression of aberrantly enhanced late Na+ current and thus may participate in the prevention of SCD and/or VAs via the restoration of the lengthened repolarization phase in the failing myocardium. The gene discussed is SLC5A2; the disease is Schnyder corneal dystrophy.